Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation

Aims We compared the 1‐year safety and effectiveness of dabigatran 110 mg (D110) or 150 mg (D150) twice daily to vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation. Methods New user cohort study of patients dispensed D110 or D150 vs. VKA in 2013 for nonvalvular atrial fibri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2019-02, Vol.85 (2), p.432-441
Hauptverfasser:	Blin, Patrick, Dureau‐Pournin, Caroline, Cottin, Yves, Bénichou, Jacques, Mismetti, Patrick, Abouelfath, Abdelilah, Lassalle, Regis, Droz, Cécile, Moore, Nicholas
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Anticoagulants - administration & dosage Anticoagulants - adverse effects Atrial Fibrillation - complications Atrial Fibrillation - drug therapy comparative effectiveness dabigatran Dabigatran - administration & dosage Dabigatran - adverse effects Dose-Response Relationship, Drug dose‐effect Embolism - epidemiology Embolism - etiology Embolism - prevention & control Female Follow-Up Studies France - epidemiology Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Incidence Male Middle Aged Original pharmacoepidemiology Prospective Studies Stroke - epidemiology Stroke - etiology Stroke - prevention & control Treatment Outcome Vitamin K - antagonists & inhibitors vitamin K antagonists
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!